FEB 2 4 2003

Correspondence in the undersigned certifies that this correspondence is

The undersigned certifies that this correspondence is being deposited this 14th day of February, 2003, as first-class mail, postage prepaid, in an envelope addressed to the Commissioner For Patents, Washington, DC 20231.

(s) Glydydd Elsa Diyardi

Response to Office Action
Application No. 10/047,935
Page 1 of 3
25212.0115-07

RECEIVED

MAR 0 3 2003

TECH CENTER 1600 2900

C.5h.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Varney et al

Examiner: Rao, Deepak. R

**SERIAL NO.:** 10/047,935

Unit: 1624

FILED: 10/23/2001

FOR: ANTIPROLIFERATIVE SUBSTITUTED 5-

THIAPYRIMIDINONE AND 5-

SELENOLYRIMIDINONE COMPOUNDS

Commissioner of Patents Washington, D.C. 20231

Sir:

## **AMENDMENTS**

This document responds to the Office Action in the above case mailed November 18, 2002, requiring a response by February 18, 2003. Accordingly this amendment is filed timely.

Please amend the application as follows:

## CLEAN COPY - PLEASE ENTER

## In the Claims:

Please delete claims \$2 and 54-61 without prejudice or disclaimer.

Please add new claim 62 as follows:

62. (New) A compound selected from the group consisting of:

N-[4-[3-(2,6-diamino-4(3H)-oxopyrimidin-5-yl)thio]propyl)benzoyl-(S)-glutamic acid;

N-[4-(N-[2-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]amino)benzoyl]- S-glutamic acid;

N-[(4-[2-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)ethyl]thio)benzoyl]-S-glutamic acid;

N-[2-(5-[3-([2,6-diamino-4(3H)-oxopyrimidin-5-yl]thio)propyl]-thienoyl)]-(S)-glutamic acid;